ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of SRT2104 on Endotoxin-induced Inflammation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01014117
Recruitment Status : Completed
First Posted : November 16, 2009
Last Update Posted : June 22, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : May 10, 2010
  Actual Study Completion Date : May 10, 2010
Publications:
van der meer, AJ, Scicluno, B, Lin, J, Jacobson, EW, Vlasuk, GP, van der Poll. The first demonstration of clinical activity by a small molcule SIRT1 activator: SRT 2104 reduces cytokine release and coagulation activation in a human enotoxin model. [Inflammation Research]. 2011;60(Supplement 1):S1-321.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):